

# CITATION REPORT

List of articles citing

Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base

DOI: 10.1016/s2213-2600(20)30172-7

Lancet Respiratory Medicine, the, 2020, 8, 539-541.

**Source:** <https://exaly.com/paper-pdf/77622133/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
92	Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 885-889	5.3	14
91	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. <i>Computational Biology and Chemistry</i> , <b>2020</b> , 89, 107372	3.6	16
90	Awareness of COVID 19 pandemic among dental practioners of Telangana state, India: A cross sectional survey. <i>Journal of Oral Biology and Craniofacial Research</i> , <b>2020</b> , 10, 484-489	2.6	10
89	Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1013	5.6	31
88	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106056	14.3	18
87	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. <i>Journal of Critical Care</i> , <b>2020</b> , 59, 176-190	4	44
86	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106101	14.3	52
85	The dynamic treatment of SARS-CoV-2 disease. <i>Baylor University Medical Center Proceedings</i> , <b>2020</b> , 33, 572-579	0.6	1
84	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. <i>Critical Care</i> , <b>2020</b> , 24, 418	10.8	36
83	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
82	Best Practices in Managing Cardiac Arrest in the Emergency Department During the COVID-19 Pandemic. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 2704-2708	6.4	1
81	Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. <i>PLoS ONE</i> , <b>2020</b> , 15, e0237130	3.7	39
80	Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. <i>Postgraduate Medical Journal</i> , <b>2021</b> , 97, 676-677	2	7
79	Awareness and Preparedness of COVID-19 Outbreak Among Healthcare Workers and Other Residents of South-West Saudi Arabia: A Cross-Sectional Survey. <i>Frontiers in Public Health</i> , <b>2020</b> , 8, 482	6	28
78	COVID-19: benefits and risks of passive immunotherapeutics. <i>Human Vaccines and Immunotherapeutics</i> , <b>2020</b> , 16, 2963-2972	4.4	5
77	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. <i>BMJ Open</i> , <b>2020</b> , 10, e041437	3	24
76	COVID-19 pandemic: A multifaceted challenge for science and healthcare. <i>Trends in Anaesthesia and Critical Care</i> , <b>2020</b> , 34, 1-3	0.4	3

75	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2020</b> , 10, 599-609	4.1	3
74	COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 581840	5.6	84
73	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). <i>Journal of Pathology</i> , <b>2020</b> , 251, 228-248	9.4	473
72	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 85	5.4	13
71	Impact of complete lockdown on total infection and death rates: A hierarchical cluster analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2020</b> , 14, 707-711	8.9	32
70	Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 2322-2324	19.7	16
69	Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research. <i>International Journal of Cardiology</i> , <b>2020</b> , 316, 285-286	3.2	1
68	Rapid publishing in the era of coronavirus disease 2019 (COVID-19). <i>Medical Journal of Australia</i> , <b>2020</b> , 212, 535-535.e1	4	4
67	Evidence for systematic autopsies in COVID-19 positive deceased: Case report of the first German investigated COVID-19 death. <i>Rechtsmedizin</i> , <b>2020</b> , 30, 1-6	0.6	26
66	Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?. <i>Journal of NeuroImmune Pharmacology</i> , <b>2020</b> , 15, 174-180	6.9	21
65	Potential specific therapies in COVID-19. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2020</b> , 14, 1753466620926853	4.9	19
64	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 591-601	3.2	55
63	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. <i>Autophagy</i> , <b>2020</b> , 16, 2260-2266	10.2	40
62	Repurposing cefuroxime for treatment of COVID-19: a scoping review of studies. <i>Journal of Biomolecular Structure and Dynamics</i> , <b>2021</b> , 39, 4547-4554	3.6	17
61	Targeting the NLRP3 Inflammasome in Severe COVID-19. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1518	8.4	185
60	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. <i>Heart Lung and Circulation</i> , <b>2020</b> , 29, 973-987	1.8	68
59	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106054	14.3	168
58	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. <i>Leukemia</i> , <b>2020</b> , 34, 1805-1815	10.7	132

57	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	14
56	A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. <i>Medicina (Lithuania)</i> , <b>2020</b> , 56,	3.1	2
55	Coronavirus disease 2019 (COVID-19): an evidence map of medical literature. <i>BMC Medical Research Methodology</i> , <b>2020</b> , 20, 177	4.7	42
54	What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials. <i>Med</i> , <b>2020</b> , 1, 9-10	31.7	5
53	Emerging Prevention and Treatment Strategies to Control COVID-19. <i>Pathogens</i> , <b>2020</b> , 9,	4.5	19
52	When science goes viral: The research response during three months of the COVID-19 outbreak. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 129, 110451	7.5	34
51	Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis". <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, e75-e76	4.5	
50	Patients with lupus are not protected from COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e21	2.4	8
49	Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2021</b> , 54, 109-112	8.5	6
48	Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13428	4.6	12
47	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , <b>2021</b> , 41, 1375-1426	14.4	11
46	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 1317-1331	5.5	9
45	Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 514-517	3.3	
44	Multi-organ damage by covid-19: congestive (cardio-pulmonary) heart failure, and blood-heart barrier leakage. <i>Molecular and Cellular Biochemistry</i> , <b>2021</b> , 476, 1891-1895	4.2	7
43	Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2021</b> , 36, 147-153	5.6	14
42	Bilingualism and COVID-19: using a second language during a health crisis. <i>Journal of Communication in Healthcare</i> , <b>2021</b> , 14, 20-30	0.9	2
41	CARDIOVASCULAR DISEASE IN COVID-19 PATIENTS. PART 2.. <i>Ţurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta</i> , <b>2021</b> , 19, 5-9	0.2	1
40	Therapeutic Strategies in the Management of COVID-19. <i>Frontiers in Molecular Biosciences</i> , <b>2020</b> , 7, 636738	3.8	8

39	The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2021</b> , 25, 85-101	1.6	4
38	Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3835-3850	3.8	1
37	Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. <i>Journal of Traditional and Complementary Medicine</i> , <b>2021</b> , 11, 144-157	4.6	15
36	Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 524	3.2	
35	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 897190021997399	1.3	1
34	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. <i>Clinical Ethics</i> , 147775092110114	1	0
33	Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 1323-1329	3.3	
32	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 675419	5.7	13
31	Electron Donor-Acceptor Capacity of Selected Pharmaceuticals against COVID-19. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	3
30	Mechanism of Action of Chloroquine/Hydroxychloroquine for Covid-19 Infection. <i>Coronaviruses</i> , <b>2021</b> , 2,	1.5	2
29	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. <i>Biologics</i> , <b>2021</b> , 1, 111-128		1
28	Potential drug leads for SARS-CoV2 from phytochemicals of : a Machine Learning approach. <i>VirusDisease</i> , <b>2021</b> , 32, 1-9	3.4	0
27	The Impact of Media on Public Health Awareness Concerning the Use of Natural Remedies Against the COVID-19 Outbreak in Saudi Arabia. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 3145-3152	2.3	4
26	Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14710	2.9	3
25	Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. <i>Annals of Medicine</i> , <b>2021</b> , 53, 318-334	1.5	10
24	Therapeutic approaches against coronaviruses acute respiratory syndrome. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00691	3.1	4
23	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , <b>2020</b> , 28, 115757	3.4	12
22	Clinical, Radiological and Therapeutic Characteristics of Patients with COVID-19 in Saudi Arabia		4

21	Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial.		14
20	Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations. <i>Therapeutic Advances in Drug Safety</i> , <b>2020</b> , 11, 2042098620957141	3.5	2
19	Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. <i>Annals of Intensive Care</i> , <b>2020</b> , 10, 131	8.9	24
18	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 2047-2061	5.9	4
17	Sustainable Post Covid19 Lockdown Strategy Through Evidence-Based Policy. <i>Integrative Journal of Medical Sciences</i> , 7,	0	5
16	Immunosuppression for COVID-19: repurposing medicines in a pandemic. <i>Australian Prescriber</i> , <b>2020</b> , 43, 106-107	1.4	4
15	Management of critically ill patients with COVID-19: suggestions and instructions from the coordination of intensive care units of Lombardy. <i>Minerva Anestesiologica</i> , <b>2020</b> , 86, 1234-1245	1.9	19
14	Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles. <i>Journal of Korean Medical Science</i> , <b>2020</b> , 35, e239	4.7	19
13	[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. <i>Experimental and Therapeutic Medicine</i> , <b>2020</b> , 20, 147-150	2.1	4
12	Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). <i>International Journal of Molecular Medicine</i> , <b>2020</b> , 46, 467-488	4.4	86
11	COVID-19 and Immunomodulatory Therapy - Can We Use Data from Previous Viral Pandemics?. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1734-1737	4.1	4
10	The prospects of employing probiotics in combating COVID-19.. <i>Tzu Chi Medical Journal</i> , <b>2022</b> , 34, 148-159.	0	0
9	Impact of complete lock-down on total infection and death rates: A hierarchical cluster analysis.		
8	Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e9	2.4	1
7	Coronavirus Disease 2019 (COVID-19): An Evidence Map of Medical Literature.		0
6	variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19. <b>2020</b> ,		
5	Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
4	Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.. <i>Journal of Trace Elements in Medicine and Biology</i> , <b>2022</b> , 71, 126954 <sup>4.1</sup>	4.1	1

3	Healthcare Management Intricacy, Governance, and Strategic Plan During the COVID-19 Pandemic (With Special Reference to India). <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , <b>2022</b> , 40-62	0.3
2	Knowledge and compliance of hydroxychloroquine prophylaxis for severe acute respiratory syndrome coronavirus 2 infection among Indian health-care workers. <b>2022</b> , 11, 33	
1	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. <b>2022</b> , 101151	3